JP2021527064A5 - - Google Patents

Info

Publication number
JP2021527064A5
JP2021527064A5 JP2020568253A JP2020568253A JP2021527064A5 JP 2021527064 A5 JP2021527064 A5 JP 2021527064A5 JP 2020568253 A JP2020568253 A JP 2020568253A JP 2020568253 A JP2020568253 A JP 2020568253A JP 2021527064 A5 JP2021527064 A5 JP 2021527064A5
Authority
JP
Japan
Prior art keywords
substituted
group
pharmaceutical composition
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020568253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527064A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035980 external-priority patent/WO2019236957A1/en
Publication of JP2021527064A publication Critical patent/JP2021527064A/ja
Publication of JP2021527064A5 publication Critical patent/JP2021527064A5/ja
Pending legal-status Critical Current

Links

JP2020568253A 2018-06-07 2019-06-07 Prc1阻害剤及びそれを用いた治療方法 Pending JP2021527064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681989P 2018-06-07 2018-06-07
US62/681,989 2018-06-07
PCT/US2019/035980 WO2019236957A1 (en) 2018-06-07 2019-06-07 Prc1 inhibitors and methods of treatment therewith

Publications (2)

Publication Number Publication Date
JP2021527064A JP2021527064A (ja) 2021-10-11
JP2021527064A5 true JP2021527064A5 (cg-RX-API-DMAC10.html) 2022-06-09

Family

ID=68769488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568253A Pending JP2021527064A (ja) 2018-06-07 2019-06-07 Prc1阻害剤及びそれを用いた治療方法

Country Status (6)

Country Link
US (2) US11319302B2 (cg-RX-API-DMAC10.html)
EP (2) EP3813784B1 (cg-RX-API-DMAC10.html)
JP (1) JP2021527064A (cg-RX-API-DMAC10.html)
CN (1) CN112533581B (cg-RX-API-DMAC10.html)
CA (1) CA3102777A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019236957A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3813784B1 (en) * 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
EP3989949A4 (en) * 2019-06-27 2023-07-12 Board of Regents, The University of Texas System INHIBITION OF PRC1 FOR THE TREATMENT OF CANCER
JP2026510538A (ja) * 2022-10-28 2026-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Stingアンタゴニストとしての複素環化合物
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510A (en) 1837-12-07 soeel
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US5863A (en) 1848-10-17 Matthias p
US5861A (en) 1848-10-17 Locking umbrella and parasol
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
WO2003068738A1 (en) * 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
WO2008023842A1 (en) * 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Methods of screening for agents that inhibit binding between mphosph1 and prc1
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012106368A2 (en) * 2011-01-31 2012-08-09 The Regents Of The University Of California Methods for inhibiting prostate cancer
AU2012221800B2 (en) * 2011-02-23 2016-10-27 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2968565A2 (en) * 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
MX370588B (es) * 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
CN106794177A (zh) * 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
GB201708457D0 (en) * 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Inhibitors of metallo-beta-lactamases
EP3813784B1 (en) * 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith

Similar Documents

Publication Publication Date Title
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
JP4344235B2 (ja) タキソール増強剤化合物
AR044856A1 (es) Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
KR960010000A (ko) 종양괴사인자(tnf)생성 저해제로서의 카테콜 디에테르 화합물
RU2015143841A (ru) Ингибиторы hdac
JP2013503139A5 (cg-RX-API-DMAC10.html)
JP2011524422A5 (cg-RX-API-DMAC10.html)
RU2017131354A (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
JP7632523B2 (ja) ベンゼン誘導体
CN114026068A (zh) Ep2拮抗剂
JP2004523561A5 (cg-RX-API-DMAC10.html)
RU2010113358A (ru) Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов
RU2016117052A (ru) Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства
JP2010535706A5 (cg-RX-API-DMAC10.html)
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
TW202241399A (zh) Ep受體拮抗藥與免疫檢查點抑制藥及/或ep受體拮抗藥之組合
JP2015502371A5 (cg-RX-API-DMAC10.html)
JP2024112835A5 (cg-RX-API-DMAC10.html)
RU2011100106A (ru) Замещенные бензимидазолы для лечения нейрофиброматоза
EP3400210A2 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
RU2482117C2 (ru) Производное 3, 8-диаминотетрагидрохинолина
JP2010520915A5 (cg-RX-API-DMAC10.html)
JP2017516824A5 (cg-RX-API-DMAC10.html)
RU2009147291A (ru) Применение ингибиторов raf для лечения рака щитовидной железы
RU2008113211A (ru) N-[1, 3,4]-тиадиазол-2-илбензолсульфонамиды, способы их получения и их применение в качестве лекарственных средств